Blarcamesine - Anavex Life Sciences
Alternative Names: AE-37 hydrochloride; ANA001-HCl; ANAVEX 2-73; Blarcamesine hydrochloride - Anavex Life SciencesLatest Information Update: 10 Apr 2026
At a glance
- Originator Anavex Life Sciences
- Developer Anavex Life Sciences; The Michael J. Fox Foundation for Parkinsons Research
- Class Antidementias; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Biphenyl compounds; Dimethylamines; Furans; Neuroprotectants; Nootropics; Small molecules; Vascular disorder therapies
- Mechanism of Action Muscarinic receptor modulators; Sigma-1 receptor agonists
-
Orphan Drug Status
Yes - Fragile X syndrome; Rett syndrome; Infantile spasms
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Rett syndrome
- Phase II/III Alzheimer's disease; Fragile X syndrome; Unspecified
- Phase II Parkinson's disease
- Phase I Angelman syndrome
- No development reported Infantile spasms
- Discontinued Amyotrophic lateral sclerosis; Anxiety disorders; Autistic disorder; Cognition disorders; Multiple sclerosis; Stroke
Most Recent Events
- 25 Mar 2026 Regulatory submission withdrawn for Alzheimer's disease (Early-stage disease) in European Union (PO)
- 23 Mar 2026 Updated efficacy data from a phase IIb/III trial in Alzheimer's disease released by Anavex Life Sciences
- 17 Mar 2026 Pharmacodynamics data from a preclinical trial in Parkinson's disease released by Anavex Life Sciences